Search Results
Nov 06, 2025, 15:23 ET Oficiálne kótovanie SERES na HKEX - využitie duálnych kapitálových platforiem „A+H" na podporu globálnej expanzie
tomuto míľniku sa SERES stal prvým čínskym výrobcom luxusných vozidiel poháňaných novou energiou (NEV), ktorý je kótovaný na trhoch s akciami A aj H. Ide o najväčšiu úvodnú verejnú ponuku (IPO) čínskej automobilky v histórii a zároveň o najväčšiu IPO automobilky na svete v tomto roku.
More news about: Seres Group Co.,Ltd.
Nov 06, 2025, 14:47 ET Nitinotes obtiene la marca CE para EndoZip™
recopilando datos reales para respaldar una mayor penetración en el mercado. Paralelamente, la compañía se está preparando para su ensayo clínico pivotal IDE en EE.UU., que respaldará la presentación ante la FDA y la entrada en el mercado de tratamiento de la obesidad más grande del mundo.
More news about: Nitinotes
Nov 06, 2025, 14:42 ET Nitinotes riceve l'approvazione del marchio CE per EndoZip™, il primo sistema di sutura completamente automatizzato per la gastroplastica restrittiva endoscopica
dati reali per supportare una più ampia penetrazione del mercato. Parallelamente, l'azienda si sta preparando per il suo fondamentale studio clinico IDE negli Stati Uniti, che supporterà la presentazione alla FDA e l'ingresso nel più grande mercato mondiale per la cura dell'obesità.
More news about: Nitinotes
Nov 06, 2025, 09:30 ET Nitinotes Receives CE Mark Approval of EndoZip™, the First Fully Automated Suturing System for Endoscopic Sleeve Gastroplasty
excellence, building clinical adoption and real-world data to support broader market penetration. In parallel, the company is preparing for its pivotal U.S. IDE trial, which will support FDA submission and entry into the world's largest obesity treatment market. About
More news about: Nitinotes
Nov 06, 2025, 09:30 ET Nitinotes Receives CE Mark Approval of EndoZip™, the First Fully Automated Suturing System for Endoscopic Sleeve Gastroplasty
excellence, building clinical adoption and real-world data to support broader market penetration. In parallel, the company is preparing for its pivotal U.S. IDE trial, which will support FDA submission and entry into the world's largest obesity treatment market. About
More news about: Nitinotes
Nov 06, 2025, 08:00 ET Artivion Announces Treatment of First Patient with Arcevo LSA in ARTIZEN Pivotal Trial
operation, making it faster and potentially safer for the patient." "We are excited to see the first patient be enrolled in the Arcevo IDE trial which represents a positive milestone for the Company, and we look forward to bringing our next generation frozen elephant trunk to more patients
More news about: Artivion, Inc.
Nov 06, 2025, 01:30 ET Meiyume di Cosmopack Asia 2025: SEEDED -- Berakar pada Kecerdasan, Terhubung Melalui Unsur Kecantikan
Memperkenalkan SEEDED Setiap inovasi bermula dari sebuah benih—sebuah ide yang siap tumbuh dan berkembang. Konsep SEEDED menggambarkan bagaimana kecerdasan, sumber bahan yang beretika, formulasi inovatif, serta kemasan
More news about: Meiyume
Nov 06, 2025, 00:17 ET Ultima Markets a Inter Miláno prenášajú svoje partnerstvo z obrazovky na štadión
je náhodná. Musí sa zaslúžiť disciplínou, víziou a jednotou," povedal Jean-Philippe Mota, predseda predstavenstva spoločnosti Ultima Markets. „Ide o tie isté vlastnosti, ktoré definujú, ako poskytujeme služby obchodníkom a formujeme značku." Partnerstvo, oznámené 29. augusta
More news about: Ultima Markets Ltd
Nov 05, 2025, 16:05 ET Talphera to Host Third Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, November 12, 2025
lead product candidate, Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).
More news about: Talphera, Inc.
Nov 05, 2025, 10:57 ET Late-Breaking Clinical Trial Results Announced at VIVA 2025
Disease Presented by: Sean P. Lyden, MD The AGILITY study is a global, prospective, multicenter, single-arm investigational device exemption (IDE) trial evaluating the Revello™ Vascular Covered Stent for treating complex peripheral artery disease (PAD) in the common/external iliac and superficial
More news about: The VIVA Foundation
Nov 05, 2025, 10:00 ET Aptori's Code-Q Closes the Loop on Application Security, From Detection to Remediation
graph of the codebase to reason about intent and generate verifiable, testable fixes. Developers can review, validate and merge directly within their IDE or CI/CD environment. The result is a closed-loop system where every confirmed finding can be remediated quickly and transparently.
More news about: Aptori
Nov 04, 2025, 15:12 ET Huawei: spoločne k zelenšej a inteligentnejšej Európe
prezident podnikového predaja spoločnosti Huawei. „Spoločne môžeme vytvoriť inteligentnejšiu a udržateľnejšiu Európu." Pokiaľ ide o technologické inovácie, Chen uviedol, že spoločnosť Huawei uviedla na trh v Európe vlajkové produkty a riešenia na pomoc podnikom pri budovaní vlastnej
More news about: Huawei Technologies
Nov 04, 2025, 14:05 ET Aqua Medical Secures FDA IDE to Study its Breakthrough Endoscopic Technology for the treatment of Type 2 Diabetes
Aqua Medical's IDE submission was supported by international data demonstrating safety and encouraging metabolic improvements. With IDE approval in place, the company is now preparing for U.S. site activation and patient enrollment. "This IDE approval is a defining moment
More news about: Aqua Medical Inc.
Nov 04, 2025, 13:30 ET Anyscale Collaborates with Microsoft to Deliver AI-Native Computing on Azure
Developer Velocity: Development teams can quickly deploy clusters from Azure Portal, run interactive development with cluster-backed IDE, and debug distributed applications with advanced dashboards. Production Resilience: Fully managed,
More news about: Anyscale
Nov 04, 2025, 12:15 ET Yadea žiari na veľtrhu EICMA 2025 s novým systémom Yadea Velax a komplexným ekosystémom nabíjania
°C. Yadea plánuje sprístupniť túto zelenú technológiu väčšiemu počtu jazdcov po celom svete rozšírením ponuky modelov poháňaných sodíkovými batériami. Ide o významný pokrok v kombinácii bezpečnosti, odolnosti a ohľadu voči životnému prostrediu. Ôsma účasť spoločnosti Yadea na veľtrhu
More news about: Yadea
Nov 04, 2025, 06:50 ET BD Achieves Milestone in AGILITY Study of Revello™ Vascular Covered Stent for Treatment of Peripheral Artery Disease
global medical technology company, announced full enrollment of the iliac artery patient cohort in its pivotal AGILITY Investigational Device Exemption (IDE) study, a prospective, multi-center study evaluating the Revello™ Vascular Covered Stent in patients with peripheral arterial disease (PAD).
More news about: BD (Becton, Dickinson and Company)
Nov 04, 2025, 06:00 ET IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
medical conference in the first half of 2026 IND clearance for IDE892 (PRMT5) received in 3Q 2025; IND filing for IDE034 (B7H3/PTK7 bispecific TOP1i ADC) complete, with IND filing for IDE574 (KAT6/7) on track for year-end 2025 Entered into an exclusive
More news about: IDEAYA Biosciences, Inc.
Nov 03, 2025, 15:30 ET E2 (Endovascular Engineering, Inc) Presents ENGULF Pivotal Study as a Late-Breaking Clinical Trial at the VIVA Conference
Investigator at Piedmont Hospital in Atlanta, today presented the positive results of the pivotal cohort of the ENGULF Investigational Device Exemption (IDE) study as a late-breaking clinical trial at the annual VIVA conference in Las Vegas. The data supports the technological advancements of the Hēlo™
More news about: Endovascular Engineering, Inc.
Oct 31, 2025, 06:48 ET Segway Powersports konsoliduje inteligenciu terénnych vozidiel a predstavuje novú vlnu terénnych vozidiel na veľtrhu EICMA 2025
komunikovať a zdieľať, sa vozidlo stáva viac než len strojom – je vaším navigátorom, komunikátoroma tvorcom obsahu. Ide o skutočnú terénnu inteligenciu. Prebudená sila – nová éra inteligentnej jazdy v teréneOd svojho
More news about: Segway Powersports
Oct 31, 2025, 04:00 ET Ultima Markets a Inter Miláno prenášajú svoje partnerstvo z obrazovky na štadión
je náhodná. Musí sa zaslúžiť disciplínou, víziou a jednotou," povedal Jean-Philippe Mota, predseda predstavenstva spoločnosti Ultima Markets. „Ide o tie isté vlastnosti, ktoré definujú, ako poskytujeme služby obchodníkom a formujeme značku." Partnerstvo, oznámené 29. augusta
More news about: Ultima Markets Ltd
Oct 30, 2025, 03:00 ET Prichádza zlom v meraní farieb: zariadenie HunterLab Agera L2
navrhnuté nielen na zlepšenie výkonu merania, ale aj na zlepšenie spôsobu, akým zákazníci zachytávajú, kvantifikujú a interpretujú údaje o farbách. Či už ide o potraviny a nápoje, plasty, liečivá alebo pokročilé materiály, používatelia môžu očakávať konzistentnosť, spoľahlivosť a údaje, ktoré priamo odrážajú
More news about: HunterLab
Oct 30, 2025, 00:26 ET Wondershare Hadirkan Inovasi Perangkat Lunak Kreatif Berbasis AI di INTI 2025, Dukung Ekosistem Digital dan Ekonomi Kreatif Indonesia
komitmennya untuk mendukung pertumbuhan ekonomi digital dan kreatif Indonesia — membantu para kreator, pendidik, dan perusahaan memanfaatkan AI untuk mengubah ide menjadi dampak nyata. Kreativitas Berbasis AI Pada ajang INTI,
More news about: Wondershare Technology
Oct 29, 2025, 21:00 ET Jenscare released its multi-product portfolio's, including LuX-Valve Plus TRINITY study, JensClip and Ken-Valve, remarkable clinical outcomes at TCT 2025 in the U.S.
therapies are limited. Further follow-ups of TRINITY trial and clinical evidence worldwide using LuX-Valve Plus system are underway. Currently, the U.S. FDA IDE-EFS for LuX-Valve Plus has completed full enrollment with excellent safety and efficacy outcomes. Meanwhile, evidence supporting
More news about: Jenscare Scientific Co., Ltd.
Oct 29, 2025, 15:08 ET Silver Wound Dressing Market to Reach USD 2,129.8 million by 2032, Growing At An 4.19% CAGR - Credence Research
and antibiofilm properties. In March 2025, Imbed Biosciences received FDA approval for an Investigational Device Exemption (IDE) to conduct a feasibility trial on its polymeric matrix containing silver and gallium ions for human donor site wound treatment.
More news about: Credence Research Inc.
Oct 29, 2025, 12:00 ET Akeyless Unveils Breakthrough Solution to Secure AI Agent Identities
AWS, GCP, and Azure IAM framework as well as OpenAI, Google Gemini, Anthropic Claude, and Grok replace static API keys with dynamic credentials, while IDE plugins for VS Code, Cursor, and GitHub Copilot bring the same protections into developer workflows. Akeyless
More news about: Akeyless